Literature DB >> 20354542

Chemotherapy: How useful is adjuvant irinotecan in stage IV CRC?

Fotios Loupakis1, Alfredo Falcone.   

Abstract

Patients who undergo hepatic surgery for initially resectable liver metastases from colorectal cancer have a 70% risk of relapse. a recent phase III randomized trial has failed to demonstrate an improvement in disease-free survival with the addition of irinotecan to 5-fluorouracil and folinic acid as adjuvant treatment for patients with radically resected colorectal cancer with liver metastases.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20354542     DOI： 10.1038/nrclinonc.2010.32

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


  10 in total

Review 1.  Oxaliplatin or irinotecan as adjuvant therapy for colon cancer: the results are in.

Authors:  Michael J O'Connell
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

2.  Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy.

Authors:  Scott Kopetz; George J Chang; Michael J Overman; Cathy Eng; Daniel J Sargent; David W Larson; Axel Grothey; Jean-Nicolas Vauthey; David M Nagorney; Robert R McWilliams
Journal:  J Clin Oncol       Date:  2009-05-26       Impact factor: 44.544

3.  A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer.

Authors:  M Ychou; W Hohenberger; S Thezenas; M Navarro; J Maurel; C Bokemeyer; E Shacham-Shmueli; F Rivera; C Kwok-Keung Choi; A Santoro
Journal:  Ann Oncol       Date:  2009-06-30       Impact factor: 32.976

4.  Liver resection for colorectal metastases.

Authors:  Y Fong; A M Cohen; J G Fortner; W E Enker; A D Turnbull; D G Coit; A M Marrero; M Prasad; L H Blumgart; M F Brennan
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

5.  A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802).

Authors:  M Ychou; J-L Raoul; J-Y Douillard; S Gourgou-Bourgade; R Bugat; L Mineur; F Viret; Y Becouarn; O Bouché; E Gamelin; M Ducreux; T Conroy; J-F Seitz; L Bedenne; A Kramar
Journal:  Ann Oncol       Date:  2009-01-29       Impact factor: 32.976

6.  Actual 10-year survival after resection of colorectal liver metastases defines cure.

Authors:  James S Tomlinson; William R Jarnagin; Ronald P DeMatteo; Yuman Fong; Peter Kornprat; Mithat Gonen; Nancy Kemeny; Murray F Brennan; Leslie H Blumgart; Michael D'Angelica
Journal:  J Clin Oncol       Date:  2007-10-10       Impact factor: 44.544

7.  Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3.

Authors:  Eric Van Cutsem; Roberto Labianca; György Bodoky; Carlo Barone; Enrique Aranda; Bernard Nordlinger; Claire Topham; Josep Tabernero; Thierry André; Alberto F Sobrero; Enrico Mini; Richard Greil; Francesco Di Costanzo; Laurence Collette; Laura Cisar; Xiaoxi Zhang; David Khayat; Carsten Bokemeyer; Arnaud D Roth; David Cunningham
Journal:  J Clin Oncol       Date:  2009-05-18       Impact factor: 44.544

8.  Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials.

Authors:  Emmanuel Mitry; Anthony L A Fields; Harry Bleiberg; Roberto Labianca; Guillaume Portier; Dongsheng Tu; Donato Nitti; Valter Torri; Dominique Elias; Chris O'Callaghan; Bernard Langer; Giancarlo Martignoni; Olivier Bouché; Franck Lazorthes; Eric Van Cutsem; Laurent Bedenne; Malcolm J Moore; Philippe Rougier
Journal:  J Clin Oncol       Date:  2008-09-15       Impact factor: 44.544

9.  Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Authors:  Leonard B Saltz; Donna Niedzwiecki; Donna Hollis; Richard M Goldberg; Alexander Hantel; James P Thomas; Anthony L A Fields; Robert J Mayer
Journal:  J Clin Oncol       Date:  2007-08-10       Impact factor: 44.544

10.  Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial.

Authors:  Bernard Nordlinger; Halfdan Sorbye; Bengt Glimelius; Graeme J Poston; Peter M Schlag; Philippe Rougier; Wolf O Bechstein; John N Primrose; Euan T Walpole; Meg Finch-Jones; Daniel Jaeck; Darius Mirza; Rowan W Parks; Laurence Collette; Michel Praet; Ullrich Bethe; Eric Van Cutsem; Werner Scheithauer; Thomas Gruenberger
Journal:  Lancet       Date:  2008-03-22       Impact factor: 79.321
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.